scholarly journals Estimating cancer treatment intensity from SEER cancer registry data: methods and implications for population-based registry studies of pediatric cancers

2020 ◽  
Vol 31 (10) ◽  
pp. 881-890
Author(s):  
Jessica L. Tobin ◽  
Stefanie M. Thomas ◽  
David R. Freyer ◽  
Ann S. Hamilton ◽  
Joel E. Milam
Keyword(s):  
Cancer Treatment ◽  
Cancer Registry ◽  
Population Based ◽  
Registry Data ◽  
Treatment Intensity ◽  
Cancer Registry Data ◽  
Pediatric Cancers ◽  
Population Based Registry

Population-based incidence estimates of uveal melanoma in Germany. Supplementing cancer registry data by case–control data

2006 ◽  
Vol 15 (2) ◽  
pp. 165-170 ◽  
Author(s):  
Andreas Stang ◽  
Andrea Schmidt-Pokrzywniak ◽  
Martin Lehnert ◽  
Donald M. Parkin ◽  
Jaques Ferlay ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Cancer Registry ◽  
Population Based ◽  
Case Control ◽  
Registry Data ◽  
Control Data ◽  
Cancer Registry Data

scholarly journals 365MO Exploring changes in glioblastoma treatment patterns in Europe and the USA with population-based cancer registry data

2020 ◽  
Vol 31 ◽  
pp. S398
Author(s):  
F. Giusti ◽  
M.D.C. Martos ◽  
S. Scoccianti ◽  
L. Neamtiu ◽  
G. Randi ◽  
...  
Keyword(s):  
Cancer Registry ◽  
Population Based ◽  
Treatment Patterns ◽  
Registry Data ◽  
Cancer Registry Data ◽  
The Usa

scholarly journals Differences in cancer survival by area-level socio-economic disadvantage: A population-based study using cancer registry data

PLoS ONE ◽  
2020 ◽  
Vol 15 (1) ◽  
pp. e0228551 ◽  
Author(s):  
Nina Afshar ◽  
Dallas R. English ◽  
Tony Blakely ◽  
Vicky Thursfield ◽  
Helen Farrugia ◽  
...  
Keyword(s):  
Cancer Registry ◽  
Cancer Survival ◽  
Population Based ◽  
Registry Data ◽  
Economic Disadvantage ◽  
Population Based Study ◽  
Cancer Registry Data

scholarly journals Feasibility of Capturing Cancer Treatment Data in the Utah All-Payer Claims Database

2019 ◽  
pp. 1-10 ◽  
Author(s):  
Mia Hashibe ◽  
Judy Y. Ou ◽  
Kimberly Herget ◽  
Dan Bolton ◽  
Jordan McPherson ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Cancer Registry ◽  
Gold Standard ◽  
High Specificity ◽  
Registry Data ◽  
Insurance Companies ◽  
Health Care Information ◽  
Claims Database ◽  
Cancer Registry Data ◽  
Treatment Data

Purpose Incompleteness of treatment data is a recognized limitation of cancer registry data. An all-payer claims database (APCD) is a tool that states use to capture health care information across systems and payer. We linked the Utah Cancer Registry (UCR) records to Utah’s statewide APCD and evaluated how this linkage led to improvements in the capture of cancer treatment information. Methods We linked cancers diagnosed and reported to the UCR with Utah APCD claims for the calendar years 2013 and 2014 using LinkPlus Software. For patients with breast or colorectal cancers, manual abstraction was completed to provide a gold-standard comparison for the treatment data obtained from the claims. Results Among 10,759 reportable cancer occurrences linked to the APCD, the claims identified additional patients with cancer who received therapies that had been unknown to the registry, increasing the proportion treated with chemotherapy from 23.7% to 27.6%, hormone therapy from 14.1% to 18.8%, immunotherapy from 4.3% to 13.2%, and radiation therapy from 24.9% to 27.5%. The APCD increased the sensitivity of treatment variables compared with the abstraction gold standard. Notably, sensitivity of hormonal therapy for breast cancer increased from 78.6% to 95.2% when augmented with APCD claims data. However, the APCD alone did not achieve as high specificity for treatment data as did the data collected through traditional registry methods. Conclusions This is the first study, to our knowledge, showing that linking cancer registry data with a statewide claims database that covers multiple insurance companies improves cancer treatment data collection. Linking of cancer registry and APCD data can improve comprehensiveness of cancer registry treatment data.

Predicting the absolute risk of dying from colorectal cancer and from other causes using population-based cancer registry data

2011 ◽  
Vol 31 (5) ◽  
pp. 489-500 ◽  
Author(s):  
Minjung Lee ◽  
Kathleen A. Cronin ◽  
Mitchell H. Gail ◽  
Eric J. Feuer
Keyword(s):  
Colorectal Cancer ◽  
Cancer Registry ◽  
Absolute Risk ◽  
Population Based ◽  
Registry Data ◽  
Cancer Registry Data ◽  
The Absolute

Incidence patterns and survival of gynecological sarcoma in Germany: Analysis of population-based cancer registry data on 2106 women, 2009-2013.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e13058-e13058
Author(s):  
Klaus Pietzner ◽  
Nina Buttmann ◽  
Jalid Sehouli ◽  
Klaus Kraywinkel
Keyword(s):  
Cancer Registry ◽  
Survival Rates ◽  
Female Genital Tract ◽  
Relative Survival ◽  
Endometrial Stromal Sarcoma ◽  
Population Based ◽  
Registry Data ◽  
Uterine Leiomyosarcoma ◽  
Cancer Registry Data ◽  
Stromal Sarcoma

e13058 Background: Sarcoma of the female genital tract are rare tumors. They are described to be associated with a poor prognosis, when compared to gynecogical carcinoma. Aim of this study was to report incidence patterns and survival rates for gynecological sarcoma in Germany. Methods: Clinical data and survival rates for patients with gynecological sarcoma diagnosed in Germany between 2009 and 2013 were extracted from the German national centre for population-based cancer registry data. Incidence patterns and 5-year-relative survival rates were calculated. Results: A total of 2,106 gynecological sarcoma (GS) were eligible for analysis. The uterus was the most common site with 87.2% of all cases. The annual age-standardized incidence rate was 7.7 per 1 million women for all gynecological sarcoma. The median age at diagnosis was 59 years. The prognosis ranged according to site and subtype from a poor 5-year-relative survival of 47.6% (uterine leiomyosarcoma) to a very good 5-year-relative survival of 97.2% (endometrial stromal sarcoma). Conclusions: Despite the rareness of gynecological sarcoma, the size of the dataset allows a differentiation of subtypes according to morphology and site of origin. Clinically relevant differences in incidence and prognosis between subgroups were observed.

Sign in / Sign up

Export Citation Format

Share Document